-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
-
Summary
-
Cerevel Therapeutics Holdings, Inc. quarterly/annual Research and Development Expense history and growth rate from Q1 2020 to Q1 2024.
- Cerevel Therapeutics Holdings, Inc. Research and Development Expense for the quarter ending March 31, 2024 was $106M, a 36.1% increase year-over-year.
- Cerevel Therapeutics Holdings, Inc. Research and Development Expense for the twelve months ending March 31, 2024 was $363M, a 19.6% increase year-over-year.
- Cerevel Therapeutics Holdings, Inc. annual Research and Development Expense for 2023 was $335M, a 19.4% increase from 2022.
- Cerevel Therapeutics Holdings, Inc. annual Research and Development Expense for 2022 was $280M, a 73.2% increase from 2021.
- Cerevel Therapeutics Holdings, Inc. annual Research and Development Expense for 2021 was $162M, a 56.7% increase from 2020.
Research and Development Expense, Trailing 12 Months (USD)
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Growth (%)